Poseida Therapeutics rises on FDA nod to begin cancer therapy study
05/07/2023 13:59
** Genetic engineering firm Poseida Therapeutics' PSTX.O
shares rise ~15% to $1.98 premarket
** PSTX says U.S. Food and Drug Administration (FDA) has
cleared its application to begin human trials for its
experimental therapy to treat certain types of cancers that
start in white blood cells
** The candidate, P-CD19CD20-ALLO1, belongs to a class of
treatments known as chimeric antigen receptor T-cell therapies
(CAR-T), which harness the body's own immune cells to recognize
and attack malignant cells - Poseida
** The therapy, being developed in partnership with Swiss
drugmaker Roche ROG.S , will be evaluated in early-stage study
that will enroll up to 70 adult patients with relapsed B-cell
cancers - Poseida
** As of last close, stock down 67.4% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com))